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It is well accepted that stimulation with T cells or with T cell-derived soluble
factors is necessary in the process of B cell maturation into Ig-secreting cells (1).
T cell-derived lymphokines (B cell stimulatory factors, BSFs)t were shown to be
involved in the regulation of B cell proliferation and differentiation (2-6). The T
cell-replacing factor (TRF)isone ofBSFs that was defined as aB cell differentiation
factor (7-10) and was considered to be an important molecule involved in T-B cell
interaction for B cell triggering (11). Naturally produced TRF by a murine TRF
producing T cell hybridoma (B151K12) triggers activated B cells or neoplastic B cell
line such as chronic B cell leukemia (BCL,) to induce differentiation into Ig-
secretingcells(8-10), topromote theirDNA synthesis(B cell growth factor II [BCGFII]
activity) (12), and to induce increased expression forIL-2 receptors (13-15). Murine
TRFhas been purified tohomogeneityand anmAbto TRFhas been developed(16).
Recently, cDNA encoding formurine and human TRF was isolated (17-19). The
studies with the use of rTRF, i.e., products of recombinant DNA technology, re-
vealed that rTRF exerts all activities demonstrated by using B151TRF and induces
cytotoxic Tcell generation in immature thymocytesin conjunction withIL-2 (killer-
helper factor [KHF] activity) (20). Moreover, purified rTRF is capable of inducing
growth and terminal differentiation ofeosinophil precursors (eosinophil differentia-
tion factor [EDF] activity) (19, 21, 22), indicating that TRF, BCGFII, KHF, and
EDF activity are mediated by a single molecule. Based on these diverse activities
ofTRF on different target cells, we proposed that TRF or BCGFII will be called
IL-5 (17).
Because IL-5 has an important role in the growth and differentiation of B cells
as well as of other hematopoietic cells such as T cells and eosinophils, the nature
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of receptor for IL-5 on the cell surface has become a matter of great interest. It is
also of importance to compare the expression of IL-5 receptors with those for BSF
1/IL-4 and BSF2/IL-6, because a single class of receptor sites for BSF-1/IL-4 and
BSF2/IL-6 was reported (23-26).
Direct measurement of IL-5 binding to cell surface receptor has been made pos-
sible by the availability of large quantities of highly purified IL-5 . For the initial
characterization of the membrane IL-5 receptors, we chose the murine chronic B
cell leukemic cell, BCLI-1120 (in vitro) as a model cell line. This cell line is able
to differentiate into IgM-secreting cells in response to IL-5 and constitutes a well-
defined model system for IL-5 action (11).
Using radiolabeled murine IL-5 we show that BCL1-1120 cells bind IL-5 spe-
cifically with high and low affinity. We further demonstrate that cell-bound IL-5
is associated with a membrane protein of 46,500 mol wt. The cell types that showed
significant levels ofhigh-affinity IL-5 binding are those responding to it. The char-
acterization of IL-5-R, both at the functional and structural levels, should give us
new insight in understanding the diverse biological activities of IL-5 on different
target cells.
Materials and Methods
Cell Lines.
￿
A lymphokine-responsive clone B20 of BCL, was isolated by limiting dilu-
tion culture of an in vitro BCL, line (purchased from American Type Culture Collection,
Rockville, MD). This clone was selected for a high levelof IgM secretion in response to IL-5.
BCL,-1120 cells were maintained in RPMI 1640 medium (Sigma Chemical Co., St. Louis,
MO) supplemented with 10% FCS (Flow Laboratories, McLean, VA), 5 x 10-5 M 2-ME,
penicillin (100 U/ml), and streptomycin (100 wg/ml). Immunological characteristics of BCL,-
B20 will be described elsewhere (Yamaguchi, N., T. Takahashi, N. Harada, and K. Takatsu.
Submitted for publication). In vivo BCLI tumor line, provided by Dr. E. S. Vitetta (Univer-
sity of Texas Health Science Center at Dallas, TX) was maintained by in vivo passage in
BALB/c mice, and was used for IL-5 assay according to the method described (10). HeLa
cells transfected with a pKCR plasmid containing the cDNA sequence encoding for mouse
IL-5 were established (27) and were kindly provided by Dr. T. Honjo, KyotoUniversity, Kyoto,
Japan. They were maintained in DME supplemented with 1017o FCS, 2-ME, penicillin, and
streptomycin. Myeloma cells lines (MOPC104E and X5563), P388D1 (macrophage tumor
line), P815 (mastocytoma cell line), and BW5147 (thymoma) cell lines were kindly provided
by Dr. T. Hamaoka, BiomedicalResearch Center, Osaka University Medical School, Osaka,
Japan. BAL.17 and L10A cell lines were kindly provided by Dr. J. Kim (National Institutes
of Health, Bethesda, MD). Stromal cell-dependent early B cell lines were established ac-
cording to the methods previously described by Ogawa et al. (28) and were then maintained
in the presence of IL-5 to let them grow IL-5 dependently. We finally established two cell
lines, J-87 and T-88, which were used in the present study.
MonoclonalAntibodies.
￿
Anti-IL-5 antibody producing rat-mouse B cell hybridoma (TB13)
(16) was transplanted intraperitoneally into BALB/c nu/nu mice. The monoclonal TB13 anti-
IL-5 antibody (IgG, class) was purified as described (16) from the ascites of TB13-bearing
nu/nu mice. An aliquot ofthe purified TB13 antibody was coupled to formyl-cellulofine beads
(Seikagaku-Kogyo, Tokyo, Japan) and was used for an immunoaffinity column. Ascites of
rat B cell hybridoma 111111 producing anti-murine BSFl/IL-4 mAb (IgG, class) (29) were
kindly provided by Drs. J . Ohara and W. E. Paul (National Institutes of Health). Purified
mouse mAb 10B1 (30) against human atrial natriuretic peptide was also used.
Recombinant IL-5.
￿
rIL-5 was prepared by methods previously described (17, 31). In brief,
murine IL-5 cDNA (pSP6K-mTRF23) was cleaved with Sal I to linearize plasmid DNA, and
mRNAs were synthesized using SP6 RNA polymerase. The synthesized RNAs were injected
in Xenopus oocytes and were incubated for 2 d at 20°C . Oocytes supernatants were collectedMITA ET AL.
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after the incubation, and were applied to an antiTRF mAb (TB13)-coupled cellulofine beads.
The samples were eluted with 50 mM acetic acid after extensive washing by the each of the
following solutions: 1 M NaCl, 0.5% NP-40, PBS, pH 7.2, and distilled water. Then, acetic
acid was evaporated by a Speed Vac Concentrator (Savant Instruments, Inc., Hicksville, NY).
The samples thus obtained were further purified by gel permeation column chromatography
with the use ofSuperose 12 connected with fast-protein liquid chromatography (FPLC; Phar-
macia Fine Chemicals, Uppsala, Sweden). Contamination of proteins other than IL-5 was
analyzed by SDS-PAGE with the use of silver staining and was <0.5'7o. We also used im-
munoaffinity-purifed IL-5 obtained from cultured supernatant ofHeLa cells which had been
transfected with mouse IL-5 cDNA. Specific activity of purified rIL-5 was calculated from
protein concentration determined by fluorescamine analysis (32) and biological activity was
determined by TRF assay as described below.
Radiolabeling of IL-5.
￿
We used both biosynthetically labeled ["S]IL-5 and externally la-
beled 1251-IL-5 for binding assay. To prepare biosynthetically labeled IL-5, 0.1 mCi
["S]methionine (1,000 Ci/mmol, Amersham Japan, Tokyo) in 10 Al was added to the 100-A1
culture in modified Barth's medium that contained 10 oocytes. After the culture, 35S-labeled
IL-5 was immunoaffinity-purified by the methods previously described (30). Purified IL-5
was labeled using diiodo-Bolton-Hunter reagent (33) (4,000 Ci/mmol; New England Nu-
clear, Boston, MA) according to the manufacturer's instructions. Briefly, 4 Ag of im-
munoaffinity-purified IL-5 dissolved in 10 Al of 0.1 M borate buffer, pH 8.5, was added to
a vial containing 500 pCi Bolton-Hunter reagent. Reaction was allowed to proceed for 30
min on ice and was stopped by addition of 500 Al of 0.2 M glycine in 0.1 M borate buffer
(pH 8.5). 500 Al of 0.25% gelatin in RPMI 1640 medium (pH 7 .2) was added as a carrier,
and labeled IL-5 was separated free from Bolton-Hunter reagent by using a gel filtration
column (PD-10, Pharmacia Fine Chemicals). Fractions containing protein-bound radioac-
tivity were pooled. 1251-labeled IL-5 was diluted with RPMI 1640, 25 mM Hepes, pH 7 .2,
1 mg/ml BSA, 100 wg/ml streptomycin, and 100 U/ml penicillin (binding medium). Purity
and molecular weight ofradiolabeled IL-5 were examined by SDS-PAGE followed by autora-
diography. SDS-PAGE analysis was carried out by the procedures described by Laemmli (34),
using 12.57o polyacrylamide gels.
BiologicalAssayfor IL-5.
￿
Biological activities of rIL-5 were assessed with the use of BCL,
(in vivo line) by polyclonal IgM plaque-forming cell (PFC) assay as described (10), and were
expressed as units/milliliter. A unit of IL-5 was determined by the amounts of IL-5 required
for half-maximal responses in the IgM PFC assay.
BindingAssay.
￿
Binding assay was performed according to the protocol described by Robb
et al. (35) with some modifications. Cells for assay were washed twice and incubated for at
least 2 h at 37°C in 50 ml RPMI 1640, 25 mM Hepes, pH 7 .2, and washed three times with
the same medium to remove any endogenous IL-5. After washing, cells were immediately
used for binding experiments. To determine the level of binding, serial dilutions of radiola-
beled IL-5 were incubated at 37°C with 1-10 x 106 cells in a total volume of 200 Al binding
medium using 1.5-ml micro test tubes (Assist Trading Co., Ltd., Tokyo, Japan). The tubes
were stirred every 10 min to avoid the aggregation of the cells. At the end of incubation,
the reaction mixture was layered onto a 200-wl mixture of 84% silicone oil (SH-550; Nakarai
Chemical Ltd., Tokyo, Japan) and 16% paraffin oil (No. 7162; Merck & Co., Inc., Rahway,
NJ) in a 400-wl polypropylene tube (Assist Trading Co., Ltd.) and were centrifuged at 12,000
rpm for 90 s to remove the small amounts of unbound IL-5 . The tips of tubes were cut-off,
placed in vials, and radioactivity was counted. When ["S]IL-5 was used as a ligand, tips
were placed in scintillation vials and the pellets were solubilized by addition of 100 Al of 1%
SDS followed by addition of 3 ml Sintisol Ex (Dojindo Laboratories, Kumamoto, Japan).
To assess equilibrium radiolabeled IL-5 binding to the BCL,-B20 cells, cells were in-
cubated at 37°C for 10 min with various concentrations of 1211-IL-5. The aliquots were re-
moved and centrifuged through a layer of oil mixture. The cell-bound and free radioactivity
were monitored as described above. The specific binding was defined as the difference be-
tween total binding and nonspecific binding in the presence of 50-100-fold molar excess of
unlabeled IL-5. The dissociation constant and an average number of binding sites per cell
were calculated by Scatchard analysis of the saturation binding data (36). The lower limit
of detection for ligands was 10 binding sites per cell.866
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Lymphokines.
￿
Human rIL-la was a gift from Ohtsuka Pharmaceutical Co. Ltd . (Toku-
shima, Japan) ; human rIL-2 was from Takeda Central Research Institutes (Toyonaka, Japan) ;
and murine IFN-y was from Shionogi Research Institutes (Osaka, Japan) . Murine rIL-3,
murine recombinant granulocyte colony-stimulating factor (G-CSF), and granulocyte/mono-
cyte colony-stimulating factor (GM-CSF) were generously provided by Drs . K. Arai and A .
Miyajima (DNAX Research Institute, Palo Alto, CA) .
Chemical Crosslinking ofIL-5 Binding Proteins on theBCL,-B20 Cell Surface .
￿
Crosslinkers dis-
uccinimidyl suberate (DSS), and ethylene glycol his succinimidyl succinate (EGS) were pur-
chased from Pierce Chemicals Co. (Rockville, IL) and used in the present study . Radiola-
beled IL-5 was crosslinked to IL-5 binding proteins accordingto the followingprotocol described
by Sabe et al . (37) . In brief, BCL I -B20 cells (10' cells) in 200 ltl of binding medium alone
or binding medium containing 100-fold excess unlabeled IL-5 were incubated with radiola-
bled IL-5 for 10 min at 37°C . Subsequently, cells were centrifuged and washed once with
1 ml HBSS and were resuspended in 500 ul HBSS . 10 pl of crosslinker (50 mM) in DMSO
were added to give a final concentration of 1 mM, and the mixture was incubated for 30
min on ice followed by the addition of 50 wl of0.5M glycine in HBSS to quench the reaction
for 5 min on ice . The cells were then washed twice with HBSS and finally resuspended in
300 ul PBS containing 1% Triton X-100, 2mM EGTA, 2 mM EDTA, 2mM PMSF, 10 uM
pepstatin, 10 uM leupeptin, 2 mM O-phenanthroline, and 200 KIU/ml aprotinin . The de-
tergent extraction mixture was incubated for 5 min on ice and then was centrifuged for 10
min at 4°C in a microfuge to remove nuclei and other cell debris . For SDS-PAGE analysis,
100 ul of cell extract was mixed with 2 x SDS sample buffer (0.06M Tris-HCI, pH 6 .8, 2%
SDS, 10% glycerol) supplemented with or without 10% 2-ME, were boiled for 5 min, and
were subjected to SDS-PAGE analysis in 7 .5% SDS polyacrylamide gels using stacking gel
procedure of Laemmli (34) . After electrophoresis, the gel was stained with Coomassie Bril-
liant Blue G-250, and exposed to AIF new RX 50 film (Fuji Photo Film Co . Ltd ., Tokyo,
Japan) at -80°C .
Results
Purity of Radiolabeled Il-5.
￿
Fig. 1 shows SDS-PAGE analysis on a slab gel of the
["S]methionine internally labeled IL-5 preparation and the 1251-Bolton-Hunter re-
agent-labeled IL-5 preparation used in the binding studies . The radiolabeled IL-5
showed a broad band with a molecular weight of 45,000-50,000 under nonreducing
conditions and migrated to a molecular weight of 23,000-26,000, indicating that
IL-5 consists of a homodimer (31) . When the radiolabeled IL-5 was treated with
N-glycanase, the sample migrated to an apparentMr of 13,000, as shown by SDS-
PAGE under reducing conditions (data not shown), indicating that heterogeneous
glycosylation may result in relatively heterogeneous IL-5 preparations .
FIGURE 1 .
￿
Autoradiograph of radiolabeled IL-5 analyzed by SDS-
PAGE . An aliquot of [35S]methionine-labeled IL-5 (105 cpm) (A) or
1251-labeled IL-5 (105 cpm) (B)was boiled with the sample buffer de-
scribed by Laemmli (34) in the presence or absence of2-ME for 5
min, andwas applied on polyacrylamide gel with 12.5% acrylamide
gels . SDS-PAGE was performed at a constant current of 25 mA ac-
cording to the methods of Laemmli (34) with a slight modification
(16) . Marker proteins used were soybean trypsin inhibitor (21,500),
carbonic anhydrase (31,000), ovalbumin (45,000), bovine serum al-
bumin (66,700), and phosphorylase B (92,500) .Comparison betweenbiological activity and determination of protein concentra-
tion ofpurified rIL-5revealed that aunit ofbiological activity ofpurified IL-5 corre-
sponds to -42 pg of protein. The specific activity of the ["S]IL-5 and 1251-IL-5
was estimated to be 6,000 cpm/42 pg or 6.5 x 1015 cpm/mmol (mol wt 46,000) and
484 cpm/42 pg or 5.3 x 1014 cpm/mmol, respectively. The specific biological ac-
tivity of 1251-IL-5 was N70% of biological activity of the material before iodina-
tion. However, comparison of the bindingof radiolabeled 1251-IL-5 with that ofun-
labeled IL-5 measured by inhibition revealed little decrease in binding activity for
BCL1-B20 cells (see below) Although biosynthetic labeling with [35S]methionine
yielded the radiolabeled IL-5 with high specific activity, it was impractical. In con-
trary, radioiodination of IL-5 using Bolton-Huntor reagent was practically easy to
handle. We chose to use mainly 1251-IL-5 for further studies. However, when we
would confirm the existence of high-affinity IL-5 binding sites, we used ["S]IL-5
preferentially.
Time-Course ofAssociation and ofDissociation ofRadiolabeled IL-5.
￿
It was observed
in our preliminary experiments that BCL)-B20 responded to IL-5 resulting in IgM-
secreting cells and bound the highest amount of radiolabeled IL-5. Therefore, the
optimal parameters for cell binding of radiolabeled IL-5 were initially determined
using cloned BCLI-B20 cells. Measurement of the time-course of association of
1251-IL-5 with these cells at 37°C revealed a rapid uptake of radiolabel with max-
imum levels within 10 min(Fig. 2A); alldata were corrected fornonspecific binding.
When the sodium azide (0.02%) that is known to inhibit membrane fluidity was
added during binding assay at 37 °C, maximum level of binding was observed, but
only after 60 min of culture. By contrast, a less than maximumlevel of bindingwas
observed at 4°C even after 3 h of incubation. We observed essentially identicalbinding
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FIGURE 2.
￿
Kinetics of radiolabeled IL-5 bindingto BCLI-
B20 cells. 2 x 106 BCLI-B20 cells in 200 ul binding
medium with 5 x 104 cpm 1251-IL-5 (A) or with 3 x 104
cpm [35S]IL-5 (B) were incubated forthe indicatedtime at
37°C in the presence or absence of 0.02% sodium azide
or at 4°C in the absence of sodium azide. Data represent
themean specific bindingofduplicate samples, whichwas
defined as the difference between the total binding and
nonspecific binding that was obtained in the presence of
100-fold excess unlabeled IL-5.868
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profile of [11S]IL-5 to the target with that of "'I-IL-5 (Fig. 2 B). Although we don't
show the data, only low levels of internalization of radiolabeled IL-5 was observed
at 37°C within 10 min. Therefore, the standard experimental condition; 10 min
of incubation at 37°C, was used throughout the study.
RadiolabeledIL-5 Binding Number ofReceptors, andAffinity.
￿
Incubation of increasing
concentrations of 1251-IL-5 with BCLi-B20 cells demonstrated that the binding con-
sisted of predominantly a saturable component (Fig. 3). Nonsaturable binding was
estimatedby including 100-fold molarexcess unlabeledIL-5 during the incubation.
The level of binding that remained was linearly dependent upon the concentration
of free 1251-IL-5 and generally constituted 10% of the total bound fraction in the
absence of unlabeled IL-5 .
Scatchard plot analysis of the binding data revealed that there were two classes
of binding sites on BCL1-1320 cells (Fig. 3, inset). The negative inverse of the regres-
sion coefficient gave adissociation constant of 66 pM (high affinity) and 12 nM (low
affinity) and an average number of high- and low-affinity receptor sites were 400
and 7,500 binding sites per cell, respectively. The ["S]IL-5 gave similar estimates
ofthe number of bindingsites and affinity constants (data not shown). We also esti-
mated the numbers of binding sites and affinity to radiolabeled IL-5 to BCLI-1320
cells at 37°C for 60 min in the presence of 0.02% NaN3 . The results revealed that
high-affinity binding sites (Kd = 55 pM) are 250 per cell and low-affinity binding
sites (Kd = 9.4 nM) are 6,200 per cell.
Characterization of IL-5-R on BCL) -1320, in terms of number of binding sites,
could be modulated by stimulating the BCLI-1320 cells in vitro with LPS for 24 h.
As shown in Fig. 4, an average number of high-affinity (Kd = 92 pM) and low-
affinity (Kd = 5.2 nM) binding sites were 1,200 and 8,400 binding sites per cell,
respectively.
Specificity ofBinding of Radiolabeled IL-5 on BCLi-B20 Cells.
￿
The specificity o£ ra-
diolabeled IL-5 binding for BCLi-B20 cells was examined by introducing a variety
of growth factors and hormones as potential competitors for the binding. As shown
in Table I (Exp. 1) and Fig. 5, unlabeled IL-5 inhibited the binding of 1251-IL-5
in a dose-dependent manner. As much as 90% of the total radioactivity of 1251-IL-
5 bound to BCLi-B20 without competitor was inhibited by 100-fold excess unla-
beled IL-5. None of the recombinant lymphokines tested had anymeasurable effect
on the bindingof 1251-IL-5 to BCL1-1320 cells. Of special note are the findings that
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Scatchard plot analysis of equilibrium
binding analysis of 1251-IL-5 to BCLI-1320 cells.
BCLI-1320 cells were incubated at 37°C with var-
ious amounts of 1251-IL-5 for 10 min. Specific
equilibrium bindingwas determined after subtrac-
tion of nonspecific bindingand the data were reex-
pressed as a Scatchard plot (inset).60
50 x
40
d
m 30
E 20
0 m 10 0
￿
4
￿
a
Bound molecules/cell x 10-3
5
￿
10
￿
15
1261-IL-5 added OM)
MITA ET AL.
￿
869
FIGURE 4. Increased expression of IL-5
binding sites by stimulating BCLI-1320 cells
with LPS. TheBCLI-1320 Cells (106/ml) were
cultured with 50 gg/ml LPS for 24 h. After
the culture cells were harvested, washed, and
subjected to the binding assay according to
the procedures as described in Fig. 3. Specific
equilibrium binding was determined after
subtraction of nonspecific binding and the
data were reexpressed as a Scatchard plot
(inset).
IL-3, GM-CSF, and IFN-y, which share amino acid sequence homology with IL-5
in short segment, did not compete for 1251-IL-5 binding. The binding of [35S]IL-5
to BCLI-1320 cells was equally inhibited by ' 251-IL-5 with unlabeled IL-5 (Fig. 5),
indicating that radiolabeled 1251-IL-5 has essentially similar binding capacity with
that of unlabeled IL-5 .
The binding of ' 211-IL-5 to its receptor was also inhibited by the TB13 anti-IL-5
(TRF) mAb, which is also a potent inhibitorofthe biologic function of IL-5. Unla-
beled naturallyproduced IL-5 from B151K12 cells (purified by usingimmunoaffinity
column and gel permeation) could inhibit 1251-IL-5 binding to BCLI-1320 cells. An-
tibody to murine BSF1IIL-4 or to human natriuretic atrial peptide failed to inhibit
binding of IL-5 to its receptor (Table I, Exp. 2).
Comparison of IL-5 Biological Activity andRadiolabeled IL-5 Binding
￿
In evaluating
the biological relevance of the binding demonstrated for radiolabeled IL-5, it was
TABLE I
Competition for the Binding of 1251-IL-5 by Unlabeled IL-5 and other
Lymphokines to BCLI-B20
Exp.
2
5 x 106 BCLI-1320 cells and 4 x 10-10 M of 12'I-IL-5 were incubated in
200 wl binding medium for 10 min at 37'C with indicated amounts of lym-
phokines or antibodies. Data are mean of duplicate samples.
Immunoafiinity-purified naturally produced IL-5 by B151K12 cells.
Inhibitor IZSMabeled IL-5 bound
cpm
None 2,879
IL-5 (4.0 x 10-8 M) 256
IL-1a (1 .4 x 10-7 M) 2,802
IL-2 (1 .5 x 10-6 M) 2,752
IL-3 (6.3 x 10- ' M) 2,998
IFN-y (8.3 x 10-7 M) 2,890
GM-CSF (5.3 x 10-e M) 2,588
None 3,372
IL-5 (2.0 x 10-8 M)' 416
Anti-IL-5 (50 pg/ml) 605
Anti-IL-4 (50 I+g/ml) 3,238
Anti-hANP (50 kg/ml) 3,428870
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ofparticular interest to compare the concentrations of IL-5 that result in significant
binding with those responsible for in vitro differentiation. Serial twofold dilutions
of [35S]IL-5 were incubated with the BCL1-B20 cells as in a standard TRF assay.
After 3 d of culture, the cells were used for PFC assay to measure their response
to the exposure to IL-5 . When the data from this experiment were compared with
the binding curve for [35S]IL-5 to BCL1-B20 cells, the concentration of IL-5 that
promoted half-maximal IgM PFC response was 2.5 pM (2 .7 U/ml) and the concen-
tration of [35S]IL-5 giving half-maximal binding was 15 pM (16.3 U/ml) (Fig. 6).
Moreover, the maximumbiological response occurred at aconcentraion ofIL-5 that
corresponded to 40-50% saturation ofthe high-affinity binding sites. The similarity
between the biological dose-response curve and the ["S]IL-5 binding curve suggests
that the biological response is proportional to the high-affinity IL-5 binding site oc-
cupancy.
Affinity Crosslinking ofRadiolabeled IL-5 to BCLI-B20 Cells.
￿
IL-5 bound to receptors
on BCL1-B20 cell surface was crosslinked with DSS or EGS according to the proce-
dures described in the Materials and Methods. Fig. 7 shows an SDS-PAGE analysis
of detergent lysates from BCL1-B20 cells that were incubated with ["S]IL-5 in the
presence or absenceofunlabeled IL-5, washed, andexposed to bivalent lysine-directed
crosslinking agents. Underthe conditions used, DSS produced a radiolabeled band
at -92,500 Mr when cell lysates were analyzed under nonreducing conditions (Fig.
7, lane 1). Thecrosslinking ofIL-5 to thehigher molecularweight specieswasspecific,
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FIGURE 5.
￿
Comparison for binding inhibitory
effect of radiolabeled IL-5 with unlabeledIL-5.
The standard bindingassaywasconductedusing
BCL1-B20 cells (2 x 106) and[3sS]IL-5 (12 pM).
Various concentrations ofeither unlabeled IL-5
or 1251-IL-5 were added as inhibitors. Since
counts of 1251-IL-5 (y-ray) overlapped with 35S
(p-ray), we monitored the overlapping of 1251
counts onto 35S counts, subtracted them from
total 35S counts, and recalculated the [35S]IL-5
real counts that bound on BCL1-B20.
FIGURE 6.
￿
Comparison betweenthepercentage ofthe
maximal biological response (IgM-secretion inducing
assay, /) and the maximal level of [35S]IL-5 binding
(")as afunction oftheconcentrationof IL-5. Each point
represents the mean of triplicate (N) or duplicate (0)
determinations.MITA ET AL.
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FIGURE 7 .
￿
Autoradiograph of crosslinking of "S]IL-5-binding
protein. BCLI-1320 cell were incubated with [CS]IL-5 (2 x 10
cpm) for 10 min at 37°C, and were washed . Then, DSS (1 mM)
was added and kept at 4°C for another 30 min. After several
washings, cells were lysed with the buffer as described in Materials
and Methodsand the lysate was analyzed with SDS-PAGE with
7.5% acrylamide gels . Autoradiography wasmade after the elec-
trophoresis.
since unlabeled IL-5 abolished the presence of bands on the gel (Fig. 7, lane 2) .
Furthermore, in the absence of crosslinking reagent, no cell-associated radiolabeled
species was detected other than IL-5 (Fig . 7, lane 3) . The uncrosslinked IL-5 ran
at the bottom of the 7.5% gels, which was 46,000M r . Essentially similar results
shown in Fig . 7 were obtained using 1251-IL-5 as shown in Fig. 8. EGS as well as
DSS produced a radiolabeled band at 92,500 under nonreducing conditions (Fig .
8 A) . There was a faint band in some but not all samples, migrating with 160,000
and 210,000M r (data not shown) .
Lysates of cells treatedwith IL-5 and these crosslinkers were also analyzed under
reducing conditions (Fig . 8 B) . Use of crosslinkers DSS and EGS resulted in the
detection ofone band in the gel: a major band of 75,000 Mr . The 75,000M r band
was detected under all conditions examined .
Cellular Distribution ofIL-5-R.
￿
Binding assay forIL-5 on various murine cell lines
was carried out . Table11 summarizes the results ofasurvey ofnumber ofcell types,
including primary cells and established cell lines, for the presence ofIL-5-R . For
FIGURE 8 .
￿
Autoradiograph of crosslinking of 125I-IL-5-binding protein. BCLI-1320 cells were
incubated with 1251-11-5 (106 cpm), and crosslinked with the use ofeither DSS (1 mM)orEGS
(1 mM) for 30 min . After the washing, cells were lysed with Triton and the lysates were subjected
to SDS-PAGE under either nonreducing (A) or reducing conditions with 5% 2-ME (B).872
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TABLE II
Cellular Distribution ofMurine IL-5 Receptors
Binding sites per cell
￿
Kd
Primary cells
￿
(Mean t SEM)
￿
(Mean t SEM)
High-affinity IL-5 receptors
PM
<10
￿
ND
<10
￿
ND
Cells were analyzed by usual binding assay. In some cells, at least five different doses of
[35S]IL-5 were used for the assay. The averages of duplicate determination were taken for
analysis.
' Normal resting Splenic B cells were stimulated with LPS (50 ug/ml) for 2 d before binding
assay .
Normal Splenic T cells were stimulated with Con A (4 4g/ml) for 2 d before binding assay,
some cells, bindingassay wasconducted over arange of five differentconcentrations
of [
35S]IL-5 and an average number of high-affinity binding sites per cell, and dis-
sociation constants were calculated by Scatchard analysis. In most cases, however,
for a preliminary survey, a single concentration of [35S]IL-5 was used, to determine
whether IL-5-R were present and their approximate abundance. Among the ana-
lyzed B cell lines, BCL1-B20 and MOPCI04E (mouse myeloma) cells displayed
significant numbers of high-affinity binding sites for IL-5 . Mouse thymomacell line,
mastocytomacell line, or macrophage tumorcell line didnotexpressdetectable number
ofIL-5 binding sites(Table II). LPS-stimulated normal B cells expressed detectable
numbers of IL-5 binding sites, whereas normal resting B cells, bone marrow cells,
and Con A-stimulated T blasts expressed few, if any. Intriguingly, two early B cell
lines (J-87 andT-88) whose growth is IL-5 dependentexpressed substantial numbers
of high-affinity binding sites for IL-5 . The data clearly show that none of the cells
have more than 103 IL-5-R with high affinity.
LPS-stimulated
Thymocytes
Splenic T cells
Con A-stimulated
B blasts'
T blasts:
40 t 10
<10
<10
<10
217 ± 50
ND
ND
ND
In vitro cell lines
Designation Cell type
BCLI-B20 B-cell leukemia (in vitro line) 243 ± 100 46 f 13
BCL1 B-cell leukemia (in vivo line) 120 f 52 43 ± 15
MOPCI04E Myeloma (IgM producer) 56 ± 7 61 f 10
X5563 Myeloma (yea producer) <10 ND
J-87 Stromal cell and IL-5-dependent 45 ± 9 41 + 17
early B cell line
T-88 IL-5-dependent early B cell line 76 t 11 38 f 16
BAL. 17 B cell lymphoma <10 ND
L10A B cell lymphoma <10 ND
MTH IL-2-dependent CTLL <10 ND
B151K12 T cell hybridoma <10 ND
P815 Mastocytoma <10 ND
P388D1 Macrophage tumor <10 NDMITA ET AL.
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Discussion
Cloning of cDNA for murine IL-5 (17, 19) and production of mAb against TRF
(16) enabled us to yield large quantities of highly purified rIL-5 and has made it
possible to examine binding sites for IL-5. We used both biosynthetically labeled
[3sS]IL-5 and externally labeled 1211-IL-5. These ligands allowed us to analyze the
bindingproperties of IL-5 and to detect the presence of specific receptors for IL-5
on plasma membrane. In our experience, it seems that too much iodination of IL-5
molecule changes its conformation. In fact, TB13 anti-IL-5 antibody does not bind
efficiently to heavily iodinated IL-5 . Therefore, we rather preferred to use ["S]IL-
5 (4,000-8,000 cpm/U) for surveyingthe characteristics andthe distributions ofhigh-
affinity binding sites. Under the condition used there was no significant difference
in the bindingaffinity between radioiodinated IL-5 andunlabeled IL-5 to itsreceptor,
as shown in Fig. 5.
The distribution of high-affinity IL-5-R among the various cell types broadly
matches the pattern of cellular IL-5 responsiveness (6, 10, 13). This is in favor of
the hypothesis that the biological effects of IL-5 are mediated by the plasma mem-
brane receptor(s) identified in these studies.
Kinetic study ofcell binding of radiolabeled IL-5 has demonstrated that binding
of radiolabeled IL-5 to BCLi-B20 cells was saturated within 10 min at 37°C (Fig.
2). This level was almost the same in the presence of 0.02% NaN3 at 37°C. In com-
parison, at 4°C less than maximum bindingwas observed even after 3 h of incuba-
tion. The binding properties of IL-5 to its receptor are similar to that for IL-2 in
terms of its rapid association to receptor sites within 10 min (34), but are different
from that for BSF2/IL-6, in that the level of binding at 0°C is higher than that
at 37°C (26). From the binding profile and the Scatchard plot analysis (Figs. 3 and
4), two classes of IL-5 binding sites were detected on BCLi-B20 cells. This is
somehow similar to IL-2-R system (38), and is different from that of BSF1/IL-4-R
(23-25) and BSF2/IL-6-Rsystem (26), in which a single class of high-affinity binding
sites are detected. Although BSF-1/IL-4 and BSF-2/IL-6 have diverse activities and
targets (39, 40) like IL-5, regulation of their signal transduction may be different
from that of IL-5 .
Unlabeled native IL-5 purified from aTRFproducing T cell hybridoma B151K12
as well as rIL-5 gave the similarinhibitory effect on the bindingof radiolabeled IL-5
on BCLi-B20 cells (Table I) . The present study clearly demonstrates that IL-5-R
only bind IL-5 but not other cytokines, especially murine IL-3, murine GM-CSF,
or IFN-y (Table I). As we have previously described, the primary structure of IL-5
has some structural homology at the NH2-terminal region with murine IL-3, mu-
rine GM-CSF, and murine IFN-y (17). The resultsrevealed that IL-5 is usingdifferent
receptors from those for IL-3, IFN-y, or GM-CSF.
Recent studies on receptors for cytokines such as IL-1, IL-2, BSF1/IL-4, BSF
2/IL-6 demonstrated that cytokines do not have strict target cell specificity (23, 26,
39, 40). Our present studies using cloned tumor cell lines revealed that BCLi cells
and MOPC104E cells expressed detectable levels of receptors for IL-5 (Table II).
As we described previously (10, 17), IL-5 induces growth and differentiation of
BCLi cells. Although we do not have concrete evidence for supporting that IL-5
acts on myeloma cells, IL-5 maypromote growth of MOPCI04E cells. Lownumbers87 4
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of high-affinity IL-5 binding sites were detected on LPS-stimulated normal B cells,
whereas resting B cells appear to express few IL-5 binding sites with high affinity,
if any. Interestingly, early B cell lines of which growth are promoted by IL-5 ex-
pressed significant, but relatively lownumbers of high-affinity binding sites for IL-5.
Thelevel ofexpression ofIL-5-binding siteswaslow, compared, for example, with
receptor levels of IL-2 on T cells (38). The maximum biologic response occurred
at IL-5 concentrations that only yield40-50% of maximalIL-5 binding. These data
are in contrast to the situation with IL-2, which gives coincident binding and bio-
logical response curves (38). Our results suggest that IL-5 may exert its biological
effects at levels of 10-100 molecules bound per cell. In this sense, the IL-5 and IL-5-
R systems seem to have analogy with IL-1 and IL-1-R Systems, as discussed by Dower
et al. (41). The reason for that occupancy of low numbers of IL-5 binding sites is
sufficient to transducebiological effect is unclear. The point to be considered is that
the absolute values for the dissociation constant and number of binding sites per
cell are dependent upon preliminary estimates of the purity and specific activity
of the radiolabeled IL-5 preparations. While ["S]IL-5 and "'I-IL-5 are reasonably
uniform with respect to size on SDS-PAGE, it has some microheterogeniety regarding
isoelectric point, whichis probably due to different glycosylation. Therefore, it may
be necessary in the future to characterize IL-5 bindingsites using radiolabeled IL-5
translated in Escherichia colt.
The characteristics of IL-5 bindingsiteswith multiple affinities resemble the results
obtained with otherpolypeptide growth factors. The receptor for epidermal growth
factor was found to display low- and high-affinity binding sites, which could be in-
terconverted (43). The receptor for IL-2 was also found to show in low and high
binding sites (38). In this case, it is well accepted that high-affinity IL-2-R consist
of heterodimers, p55 and p75 (43-45). We have no concrete evidence at this mo-
ment to support either possibility.
The crosslinking experiments provided some preliminary structural information
for IL-5-R protein on the murine BCLi cell. The most likely candidate for the IL-
5-binding protein is the one with a molecule of46,500 Mr. This protein, when cross-
linked to '211-IL-5, resulted in a 92,500 Mr band on SDS-PAGE under nonreducing
conditions (Figs. 7 and 8). The 92,500 Mr protein was detected under all condi-
tions used so far. The protein mixture of 92,500 Mr protein migrated on reducing
gels at the 75,000 M r protein band (Fig. 8 B). There are at least three possibilities
to account forthis observation. Ifthere are ways that can be considered to intercon-
vert high- andlow-affinity IL-5 bindingsites, as was done forthe nerve growth factor
receptor (46, 47), the IL-5-binding protein maybe covalently linked to themonomer
form of IL-5 . If we assume that IL-5-R consists of a heterodimer, as was demon-
stratedfor the IL-2-R as well as IL-3 (43-45, 48), the IL-5-binding protein (29,000
Mr) may not be covalently linked to the other (17,500Mr) as part of a receptor com-
plex. Third, unidentified receptor-associated molecules exist that may not be de-
tected by crosslinking studies using DSS or EGS. Neither possibility is mutually
exclusive at this moment.
IL-5 seemsto be engaged as a potent factor, as far as we can see, which is capable
of inducing growth anddifferentiation of murine B cellsin an antigen-specific manner
or polyclonal way. It is not clear, however, howIL-5 manipulates growth and differen-
tiation of B cells in asingle cell level. In otherwords, IL-5 can provideboth growth-MITA ET AL.
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and differentiation-inducing signals to B cells at the same time, or each signal is
effective on B cells in a certain stageof differentiation or on B cellsin different stages
of every cell cycle. Moreover, IL-5 has diverse activities on different targets. In this
respect, analysis of regulatory mechanisms of expression of IL-5-R is extremely im-
portant.
Experimental systems described in this studywill give us further insight forinves-
tigating the molecularnature of IL-5-R. The availability ofan assay system for the
presence of IL-5-R makes it possible to screen for mAbs directed against IL-5-R,
andto survey forcell lines expressing high levels of IL-5-R. These will be important
steps toward isolating and characterizing the receptor protein(s) and the gene(s) that
encode for IL-5-R.
Summary
T cell-replacing factor (TRF)/IL-5 is a glycosylated polypeptide that acts as a
key factor forB cell growth and differentiation. Since IL-5 action is probably medi-
ated by specific cell surface receptor(s), we have characterized the binding of IL-5
to cells using biosynthetically ["Slmethionine-labeled IL-5 and "'I-IL-5 that had
been prepared usingBolton-Hunter reagent. The radiolabeled IL-5 binds specifically
to BCL1-B20 (in vitro line) (a murine chronic B cell leukemic cell line previously
shown to differentiate into IgM-secreting cells in response to IL-5) within 10 min
at 37°C. There are two classes of binding sites with high affinity (Kd = 66 pM)
and low affinity (Kd = 12 nM) for IL-5 and an average number of binding sites
for high affinity and for low affinity were 400 and 7,500 per cell, respectively. The
specificity ofbindingof radiolabeled IL-5 has been confirmedby demonstrating that
only unlabeled IL-5 and anti-IL-5 mAb but not by IL-1, IL-2, IL-3, IFN-y, and
GM-CSF inhibit radiolabeled IL-5 binding to BCLi-B20 cells. Treatment of
surface-bound radiolabeled IL-5 with bivalent crosslinkers identified a membrane
polypeptide of Mr 46,500 to which IL-5 is crosslinked.
A variety of cell types have been surveyed for the capacity to bind specifically ra-
diolabeled IL-5 with high affinity. BCL1 cells MOPC104E (murine myeloma cell
line) expressed IL-5-R, whereas BAL. 17 and L10 A (B cell lymphoma) did not.
T cell line, mastocytoma cell line, or macrophage tumor cell line did not display
detectable levels of IL-5-R. IL-5-R were hardly detectable on normal resting B cells
but were expressed on LPS-activated B cells, fitting the function of IL-5 that acts
on activated B cells for theirdifferentiation into Ig-secreting cells. Intriguingly, early
B cell lines (J-87 and T88) that grow in the presence of IL-5 expressed significant
but lownumbers of high-affinitybinding sites for IL-5 . Thebiological effects of IL-5
were mediated by high-affinity binding sites. The identification and characteriza-
tion of IL-5-R should provide new insight into the apparent diverse biological ac-
tivities of IL-5.
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